Lubiprostone
Medication used for constipation / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Lubiprostone?
Summarize this article for a 10 year old
Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company.
Clinical data | |
---|---|
Trade names | Amitiza |
Other names | RU-0211 SPI-0211 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607034 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Negligible |
Protein binding | 94% |
Metabolism | Extensive, CYP not involved |
Elimination half-life | Unknown (lubiprostone) 0.9–1.4 hours (main metabolite) |
Excretion | Kidney (60%) and fecal (30%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.107.168 |
Chemical and physical data | |
Formula | C20H32F2O5 |
Molar mass | 390.468 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
The drug was developed by Sucampo Pharmaceuticals and approved by the Food and Drug Administration (FDA) in 2006.[2][3][4] It was recommended for use in the UK by the National Institute for Health and Care Excellence (NICE) in July 2014.[5] Health Canada approved the drug in 2015.[6] Lubiprostone received approval from the Food and Drug Administration in 2008, to treat irritable bowel syndrome with constipation (IBS-C),[7] and in 2013, for the treatment of opioid-induced constipation in adults with chronic noncancer pain.[4] It is available as a generic medication.[8]